Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 2/2020

Open Access 01-12-2020 | Multiple Sclerosis | Brief Report

Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment

Authors: Christine Lebrun-Frenay, Ilona Berestjuk, Mikael Cohen, Sophie Tartare-Deckert

Published in: Neurology and Therapy | Issue 2/2020

Login to get access

Abstract

Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine’s mechanism of action, an increased risk of malignancies was suspected from the number of cancers that occurred in the 3.5 mg/kg-treated arm (CLARITY study). We showed that cladribine inhibits cell proliferation on three melanoma cell lines tested, irrespectively of their mutational oncogenic status and invasive/metastatic potential. Aggregated safety data demonstrated that the risk of melanoma is not confirmed.
Literature
1.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.CrossRefPubMed
2.
Leist TP, Comi G, Cree BAC, Coyle PK, Freedman MS, Hartung HP, Vermersch P, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257–67.CrossRefPubMed
3.
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e158.CrossRefPubMedPubMedCentral
4.
Lebrun C, Rocher F. Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs. CNS Drugs. 2018;378(2):169-13.
5.
Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, et al. Decreased prevalence of cancer in patients with multiple sclerosis: a case-control study. PLoS One. 2017;12(11):e0188120-11.CrossRef
6.
Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol. 2011;258(7):1304–11.CrossRefPubMed
7.
Girard CA, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Prod’homme V, Mallavialle A, et al. A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma. Cancer Res. 2020;80(10):1927–41.CrossRefPubMed
8.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594–604.CrossRefPubMed
9.
Cook S, Leist T, Comi G, Montalbán X, Giovannoni G, Nolting A, Hicking C, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis. An integrated analysis. Mult Scler Relat Dis. 2019;29:157–67.CrossRef
Metadata
Title
Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment
Authors
Christine Lebrun-Frenay
Ilona Berestjuk
Mikael Cohen
Sophie Tartare-Deckert
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2020
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-020-00204-5

Other articles of this Issue 2/2020

Neurology and Therapy 2/2020 Go to the issue

Original Research

Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses

Review

A Review of the Recent Findings in Minimally Invasive Treatment Options for the Management of Occipital Neuralgia

Review

A Narrative Review of the Role of Transthyretin in Health and Disease

Commentary

A Call to Action: The Role of Healthcare Providers in Reducing the Burden Associated with Neurogenic Orthostatic Hypotension

Original Research

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Original Research

Reliability and Validity of the Persian Version of the Mini-Balance Evaluation Systems Test in Patients with Stroke